ArticleEuropean archives of psychiatry and clinical neuroscience2026
The potential role of ANXA11/ANXA3 protein level ratio in predicting antidepressant treatment outcomes.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the causal relationship between 2,821 plasma protein level ratios and antidepressant treatment response to uncover the potential molecular mechanisms.
methodsWe utilized the protein level ratio dataset from the UK Biobank Pharma Proteomics Project (UKB PPP) and the antidepressant treatment dataset from the Psychiatric Genomics Consortium. We employed Mendelian Randomization (MR) analysis to explore the causal relationships between 2,821 protein level ratios and antidepressant treatment. Additionally, we conducted GO/KEGG analysis to uncover associated biological processes, cellular components, molecular functions, and signaling pathways.
resultsWe found that the protein level ratio of ANXA11/ANXA3 was significantly positively associated with the positive effects of antidepressant treatment(IVW method(FEM): OR = 1.537, 95%CI = 1.263-1.869, p = 1.730E-05, pFDR = 0.049), suggesting its potential as a biomarker for predicting antidepressant efficacy. Moreover, the GO/KEGG analysis provided new insights into the genetic architecture and molecular mechanisms underlying antidepressant efficacy.
conclusionOur results highlight the significance of protein level ratios in the pathophysiological processes of depression and offer novel strategies for the development of personalized treatment approaches. Future studies are warranted to further validate these findings and explore their clinical implications.
Indexed as
Identifiers
40956419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.